|Day Low/High||10.01 / 10.62|
|52 Wk Low/High||9.50 / 27.02|
The company's new CEO tells analysts it continues to believe the novel painkiller Nucynta can be a blockbuster.
Depomed unveiled steps the company is taking to shore itself up.
Here are Wednesday's top research calls, including downgrades for Allergan and General Dynamics, and upgrades for Coach and Occidental Petroleum.
CYBE, TIS, HUBG, DEPO and ETH all recently were downgraded by TheStreet's Quant Ratings.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ALOT, BOOM, BWA, DAR, EHTH, ESRT, ETR, FNGN, FOE, FPO, FSS, GGG, KKR, KRA, MSCC, TOT, TZOO, WMAR Downgrades: BABY, CREG, DEPO, ETH, EXPE, GNRC, SPOK, TDC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Investors in Depomed Inc saw new options begin trading this week, for the December 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 234 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.
Former Abbott Executive Brings Over 25 Years of Pharmaceutical Industry Experience
Washington needs to do more, Gottlieb says at his confirmation hearing.
Sage Therapeutics, Depomed and NantKwest were among the biotech stock movers in premarket trading on Friday.
Vertex Pharmaceuticals, Sangamo Therapeutics and Depomed were among the biotech stock movers in premarket trading on Wednesday.
Depomed settles with activist investor Starboard and replaces its CEO and two board members.
The U.S. Centers for Disease Control and Prevention says 91 Americans die every day as a result of an overdose.
The biotech company will either pick up assets to grow or sell itself to a larger company in the space, its chief financial officer told a conference.
Investors in Depomed Inc saw new options begin trading this week, for the May 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new May 19th contracts and identified one put and one call contract of particular interest.
Investors in Depomed Inc saw new options become available this week, for the April 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the DEPO options chain for the new April 21st contracts and identified one put and one call contract of particular interest.
While companies in the opiod sector have had to deal with headlines about abuse as well as pharma pricing controversies, Depomed reported increased sales across its product line.